Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Kexian Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1293-5538; OpenAlex author ID A5103019656. Sources: OpenAlex.

Their work

Papers
11 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers

Papers 11

  1. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. First author DOI 10.1186/s13045-023-01506-5↗
  2. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis First author DOI 10.21203/rs.3.rs-2411868/v1↗
  3. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. First author DOI 10.1186/s13045-022-01338-9↗
  4. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis First author DOI 10.21203/rs.3.rs-1516835/v1↗
  5. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  6. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implicati… First author DOI 10.3389/fcell.2021.619549↗
  7. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fcell.2021.665161↗
  8. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.650264↗
  9. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fmolb.2021.659168↗
  10. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.676291↗
  11. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02527-1↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zengyu Feng · 11 shared papers, 2020–2023 · strength 1.62
  2. Chenghong Peng · 10 shared papers, 2021–2023 · strength 1.50
  3. Yulian Wu · 5 shared papers, 2021 · strength 0.79
  4. Kai Qin · 5 shared papers, 2022–2023 · strength 0.70
  5. Lingxi Jiang · 5 shared papers, 2020–2023 · strength 0.68
  6. Hao Chen · 3 shared papers, 2022–2023 · strength 0.45
  7. Jiewei Lin · 3 shared papers, 2022–2023 · strength 0.41
  8. Lijie Han · 3 shared papers, 2022–2023 · strength 0.41
  9. Yizhi Cao · 3 shared papers, 2022–2023 · strength 0.41
  10. Yongsheng Jiang · 3 shared papers, 2022–2023 · strength 0.41
  11. Hao Chen · 3 shared papers, 2020–2022 · strength 0.38
  12. Jiancheng Wang · 2 shared papers, 2022–2023 · strength 0.28
  13. Jiaxin Luo · 2 shared papers, 2022–2023 · strength 0.28
  14. Baiyong Shen · 1 shared paper, 2023 · strength 0.16
  15. Hao Qian · 1 shared paper, 2021 · strength 0.16
  16. L. Jiang · 1 shared paper, 2023 · strength 0.15
  17. Tao Li · 1 shared paper, 2021 · strength 0.15
  18. Baiyong Shen · 1 shared paper, 2022 · strength 0.14
  19. Peng Chen · 1 shared paper, 2022 · strength 0.13
  20. Jiancheng Wang · 1 shared paper, 2022 · strength 0.13
  21. Chenghong Peng · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.